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Background: A novel human coronavirus, severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2), was identified in
China in December 2019. There is limited support for many of its
key epidemiologic features, including the incubation period for
clinical disease (coronavirus disease 2019 [COVID-19]), which
has important implications for surveillance and control activities.
Objective: To estimate the length of the incubation period of
COVID-19 and describe its public health implications.
Design: Pooled analysis of confirmed COVID-19 cases reported
between 4 January 2020 and 24 February 2020.
Setting: News reports and press releases from 50 provinces,
regions, and countries outside Wuhan, Hubei province, China.
Participants: Persons with confirmed SARS-CoV-2 infection out-
side Hubei province, China.
Measurements: Patient demographic characteristics and dates
and times of possible exposure, symptom onset, fever onset,
and hospitalization.
Results: There were 181 confirmed cases with identifiable expo-
sure and symptom onset windows to estimate the incubation
period of COVID-19. The median incubation period was esti-
mated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of
those who develop symptoms will do so within 11.5 days (CI, 8.2
to 15.6 days) of infection. These estimates imply that, under con-
servative assumptions, 101 out of every 10 000 cases (99th per-
centile, 482) will develop symptoms after 14 days of active mon-
itoring or quarantine.
Limitation: Publicly reported cases may overrepresent severe
cases, the incubation period for which may differ from that of
mild cases.
Conclusion: This work provides additional evidence for a me-
dian incubation period for COVID-19 of approximately 5 days,
similar to SARS. Our results support current proposals for the
length of quarantine or active monitoring of persons potentially
exposed to SARS-CoV-2, although longer monitoring periods
might be justified in extreme cases.
Primary Funding Source: U.S. Centers for Disease Control and
Prevention, National Institute of Allergy and Infectious Diseases,
National Institute of General Medical Sciences, and Alexander
von Humboldt Foundation.
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In December 2019, a cluster of severe pneumoniacases of unknown cause was reported in Wuhan, Hu-
bei province, China. The initial cluster was epidemio-
logically linked to a seafood wholesale market in Wu-
han, although many of the initial 41 cases were later
reported to have no known exposure to the market (1).
A novel strain of coronavirus belonging to the same
family of viruses that cause severe acute respiratory
syndrome (SARS) and Middle East respiratory syn-
drome (MERS), as well as the 4 human coronaviruses
associated with the common cold, was subsequently
isolated from lower respiratory tract samples of 4 cases
on 7 January 2020 (2). Infection with the virus, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), can be asymptomatic or can result in mild to severe
symptomatic disease (coronavirus disease 2019 [COVID-
19]) (3). On 30 January 2020, the World Health Organiza-
tion declared that the SARS-CoV-2 outbreak constituted a
Public Health Emergency of International Concern, and
more than 80 000 confirmed cases had been reported
worldwide as of 28 February 2020 (4, 5). On 31 January
2020, the U.S. Centers for Disease Control and Prevention
announced that all citizens returning from Hubei prov-
ince, China, would be subject to mandatory quarantine
for up to 14 days (6).
Our current understanding of the incubation pe-
riod for COVID-19 is limited. An early analysis based on
88 confirmed cases in Chinese provinces outside Wu-
han, using data on known travel to and from Wuhan to
estimate the exposure interval, indicated a mean incu-
bation period of 6.4 days (95% CI, 5.6 to 7.7 days), with
a range of 2.1 to 11.1 days (7). Another analysis based
on 158 confirmed cases outside Wuhan estimated a
median incubation period of 5.0 days (CI, 4.4 to 5.6
days), with a range of 2 to 14 days (8). These estimates
are generally consistent with estimates from 10 con-
firmed cases in China (mean incubation period, 5.2
days [CI, 4.1 to 7.0 days] [9]) and from clinical reports of
a familial cluster of COVID-19 in which symptom onset
occurred 3 to 6 days after assumed exposure in Wuhan
(1). These estimates of the incubation period of SARS-
CoV-2 are also in line with those of other known human
coronaviruses, including SARS (mean, 5 days; range, 2
to 14 days [10]), MERS (mean, 5 to 7 days; range, 2 to
14 days [11]), and non-SARS human coronavirus (mean,
3 days; range, 2 to 5 days [12]).
The incubation period can inform several impor-
tant public health activities for infectious diseases, in-
cluding active monitoring, surveillance, control, and
modeling. Active monitoring requires potentially ex-
posed persons to contact local health authorities to re-
port their health status every day. Understanding the
length of active monitoring needed to limit the risk for
missing SARS-CoV-2 infections is necessary for health
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departments to effectively use limited resources. In this
article, we provide estimates of the incubation period of
COVID-19 and the number of symptomatic infections
missed under different active monitoring scenarios.
METHODS
Data Collection
We searched for news and public health reports of
confirmed COVID-19 cases in areas with no known
community transmission, including provinces, regions,
and countries outside Hubei. We searched for reports
in both English and Chinese and abstracted the data
necessary to estimate the incubation period of COVID-
19. Two authors independently reviewed the full text of
each case report. Discrepancies were resolved by dis-
cussion and consensus.
For each case, we recorded the time of possible
exposure to SARS-CoV-2, any symptom onset, fever on-
set, and case detection. The exact time of events was
used when possible; otherwise, we defined conserva-
tive upper and lower bounds for the possible interval of
each event. For most cases, the interval of possible
SARS-CoV-2 exposure was defined as the time be-
tween the earliest possible arrival to and latest possible
departure from Wuhan. For cases without history of
travel to Wuhan but with assumed exposure to an in-
fectious person, the interval of possible SARS-CoV-2 ex-
posure was defined as the maximum possible interval
of exposure to the infectious person, including time be-
fore the infectious person was symptomatic. We al-
lowed for the possibility of continued exposure within
known clusters (for example, families traveling to-
gether) when the ordering of transmission was unclear.
We assumed that exposure always preceded symptom
onset. If we were unable to determine the latest expo-
sure time from the available case report, we defined
the upper bound of the exposure interval to be the
latest possible time of symptom onset. When the earli-
est possible time of exposure could not be determined,
we defined it as 1 December 2019, the date of symp-
tom onset in the first known case (1); we performed a
sensitivity analysis for the selection of this universal
lower bound. When the earliest possible time of symp-
tom onset could not be determined, we assumed it to
be the earliest time of possible exposure. When the
latest time of possible symptom onset could not be
determined, we assumed it to be the latest time of pos-
sible case detection. Data on age, sex, country of
residence, and possible exposure route were also
collected.
Statistical Analysis
Cases were included in the analysis if we had infor-
mation on the interval of exposure to SARS-CoV-2 and
symptom onset. We estimated the incubation time us-
ing a previously described parametric accelerated fail-
ure time model (13). For our primary analysis, we as-
sumed that the incubation time follows a log-normal
distribution, as seen in other acute respiratory viral in-
fections (12). We fit the model to all observations, as
well as to only cases where the patient had fever and
only those detected inside or outside mainland China
in subset analyses. Finally, we also fit 3 other commonly
used incubation period distributions (gamma, Weibull,
and Erlang). We estimated median incubation time and
important quantiles (2.5th, 25th, 75th, and 97.5th per-
centiles) along with their bootstrapped CIs for each
model.
Using these estimates of the incubation period, we
quantified the expected number of undetected symp-
tomatic cases in an active monitoring program, adapt-
ing a method detailed by Reich and colleagues (14).
We accounted for varying durations of the active mon-
itoring program (1 to 28 days) and individual risk for
symptomatic infection (low risk: 1-in-10 000 chance of
infection; medium risk: 1-in-1000 chance; high risk:
1-in-100 chance; infected: 1-in-1 chance). For each
bootstrapped set of parameter estimates from the log-
normal model, we calculated the probability of a symp-
tomatic infection developing after an active monitoring
program of a given length for a given risk level. This
model conservatively assumes that persons are ex-
posed to SARS-CoV-2 immediately before the active
monitoring program and assumes perfect ascertain-
ment of symptomatic cases that develop under active
monitoring. We report the mean and 99th percentile of
the expected number of undetected symptomatic
cases for each active monitoring scenario.
All estimates are based on persons who developed
symptoms, and this work makes no inferences about
asymptomatic infection with SARS-CoV-2. The analyses
were conducted using the coarseDataTools and active-
monitr packages in the R statistical programming lan-
guage, version 3.6.2 (R Foundation for Statistical Com-
puting). All code and data are available at https:
//github.com/HopkinsIDD/ncov_incubation (release at
time of submission at https://zenodo.org/record/3692048)
(15).
Role of the Funding Source
The findings and conclusions in this manuscript are
those of the authors and do not necessarily represent
the views of the U.S. Centers for Disease Control and
Prevention, the National Institute of Allergy and Infectious
Diseases, the National Institute of General Medical Sci-
ences, and the Alexander von Humboldt Foundation. The
funders had no role in study design, data collection and
analysis, preparation of the manuscript, or the decision to
submit the manuscript for publication.
RESULTS
We collected data from 181 cases with confirmed
SARS-CoV-2 infection detected outside Hubei province
before 24 February 2020 (Table 1). Of these, 69 (38%)
were female, 108 were male (60%), and 4 (2%) were of
unknown sex. The median age was 44.5 years (inter-
quartile range, 34.0 to 55.5 years). Cases were col-
lected from 24 countries and regions outside mainland
China (n = 108) and 25 provinces within mainland
China (n = 73). Most cases (n = 161) had a known re-
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cent history of travel to or residence in Wuhan; others
had evidence of contact with travelers from Hubei or
persons with known infection. Among those who devel-
oped symptoms in the community, the median time
from symptom onset to hospitalization was 1.2 days
(range, 0.2 to 29.9 days) (Figure 1).
Fitting the log-normal model to all cases, we esti-
mated the median incubation period of COVID-19 to
be 5.1 days (CI, 4.5 to 5.8 days) (Figure 2). We esti-
mated that fewer than 2.5% of infected persons will
show symptoms within 2.2 days (CI, 1.8 to 2.9 days) of
exposure, and symptom onset will occur within 11.5
days (CI, 8.2 to 15.6 days) for 97.5% of infected per-
sons. The estimate of the dispersion parameter was
1.52 (CI, 1.32 to 1.72), and the estimated mean incuba-
tion period was 5.5 days.
To control for possible bias from symptoms of
cough or sore throat, which could have been caused by
other more common pathogens, we performed the
same analysis on the subset of cases with known time of
fever onset (n = 99), using the time from exposure to
onset of fever as the incubation time. We estimated the
median incubation period to fever onset to be 5.7 days
(CI, 4.9 to 6.8 days), with 2.5% of persons experiencing
fever within 2.6 days (CI, 2.1 to 3.7 days) and 97.5%
having fever within 12.5 days (CI, 8.2 to 17.7 days) of
exposure.
Because assumptions about the occurrence of local
transmission and therefore the period of possible ex-
posure may be less firm within mainland China, we also
analyzed only cases detected outside mainland China
(n = 108). The median incubation period for these
cases was 5.5 days (CI, 4.4 to 7.0 days), with the 95%
range spanning from 2.1 (CI, 1.5 to 3.2) to 14.7 (CI, 7.4
to 22.6) days. Alternatively, persons who left mainland
China may represent a subset of persons with longer
incubation periods, persons who were able to travel
internationally before symptom onset within China, or
persons who may have chosen to delay reporting
Table 1. Characteristics of Patients With Confirmed
COVID-19 Included in This Analysis (n = 181)*
Characteristic Value





Exposure to Wuhan, n (%)
Resident of Hubei province 84 (46.4)
Known travel to Wuhan 77 (42.5)
None/unknown 20 (11.0)
COVID-19 = coronavirus disease 2019.
* Regions of case detection include mainland China (n = 73), Singa-
pore (n = 16), Japan (n = 13), Taiwan (n = 10), Hong Kong (n = 8),
South Korea (n = 8), Thailand (n = 8), Malaysia (n = 7), Australia (n = 6),
Macau (n = 5), the United States (n = 5), France (n = 4), the Philippines
(n = 3), Canada (n = 2), Italy (n = 2), Vietnam (n = 2), Brazil (n = 1),
Cambodia (n = 1), Finland (n = 1), Germany (n = 1), Lebanon (n = 1),
Nepal (n = 1), Sri Lanka (n = 1), Sweden (n = 1), and the United Arab
Emirates (n = 1).
Figure 1. SARS-CoV-2 exposure (blue), symptom onset 
(red), and case detection (green) times for 181 confirmed 
cases.
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Shaded regions represent the full possible time intervals for exposure,
symptom onset, and case detection; points represent the midpoints of
these intervals. SARS-CoV-2 = severe acute respiratory syndrome
coronavirus 2.
Figure 2. Cumulative distribution function of the
COVID-19 incubation period estimate from the
log-normal model.
























The estimated median incubation period of COVID-19 was 5.1 days
(CI, 4.5 to 5.8 days). We estimated that fewer than 2.5% of infected
persons will display symptoms within 2.2 days (CI, 1.8 to 2.9 days) of
exposure, whereas symptom onset will occur within 11.5 days (CI, 8.2
to 15.6 days) for 97.5% of infected persons. Horizontal bars represent
the 95% CIs of the 2.5th, 50th, and 97.5th percentiles of the incubation
period distribution. The estimate of the dispersion parameter is 1.52
(CI, 1.32 to 1.72). COVID-19 = coronavirus disease 2019.
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symptoms until they left China. Based on cases de-
tected inside mainland China (n = 73), the median in-
cubation period is 4.8 days (CI, 4.2 to 5.6 days), with a
95% range of 2.5 (CI, 1.9 to 3.5) to 9.2 (CI, 6.4 to 12.5)
days. Full results of these sensitivity analyses are pre-
sented in Appendix Table 1 (available at Annals.org).
We fit other commonly used parameterizations of
the incubation period (gamma, Weibull, and Erlang dis-
tributions). The incubation period estimates for these
alternate parameterizations were similar to those from
the log-normal model (Appendix Table 2, available at
Annals.org).
Given these estimates of the incubation period, we
predicted the number of symptomatic infections we
would expect to miss over the course of an active mon-
itoring program. We classified persons as being at high
risk if they have a 1-in-100 chance of developing a
symptomatic infection after exposure. For an active
monitoring program lasting 7 days, the expected num-
ber of symptomatic infections missed for every 10 000
high-risk persons monitored is 21.2 (99th percentile,
36.5) (Table 2 and Figure 3). After 14 days, it is highly
unlikely that further symptomatic infections would be
undetected among high-risk persons (mean, 1.0 unde-
tected infections per 10 000 persons [99th percentile,
4.8]). However, substantial uncertainty remains in the
classification of persons as being at “high,” “medium,”
or “low” risk for being symptomatic, and this method
does not consider the role of asymptomatic infection.
We have created an application to estimate the propor-
tion of missed COVID-19 cases across any active mon-
itoring duration up to 100 days and various population
risk levels (16).
DISCUSSION
We present estimates of the incubation period
for the novel coronavirus disease (COVID-19) that
emerged in Wuhan, Hubei province, China, in 2019.
We estimated the median incubation period of
COVID-19 to be 5.1 days and expect that nearly all in-
fected persons who have symptoms will do so within 12
days of infection. We found that the current period of
active monitoring recommended by the U.S. Centers
for Disease Control and Prevention (14 days) is well
supported by the evidence (6). Symptomatic disease is
frequently associated with transmissibility of a patho-
gen. However, given recent evidence of SARS-CoV-2
transmission by mildly symptomatic and asymptomatic
persons (17, 18), we note that time from exposure to
onset of infectiousness (latent period) may be shorter
than the incubation period estimated here, with impor-
tant implications for transmission dynamics.
Our results are broadly consistent with other esti-
mates of the incubation period (1, 7–9). Our analysis,
which was based on 181 confirmed COVID-19 cases,
made more conservative assumptions about the possi-
ble window of symptom onset and the potential for
continued exposure through transmission clusters out-
side Wuhan. Of note, the use of fixed times of symptom
onset, as used in 3 of the 4 prior analyses, will truncate
the incubation period distribution by either decreasing
the maximum possible incubation period (if the earliest
possible time of symptom onset is used) or increasing
the minimum possible incubation period (if the mid-
point or latest possible time of symptom onset is used).
Therefore, using a symptom onset window more accu-
Table 2. Expected Number of Symptomatic SARS-CoV-2 Infections That Would Be Undetected During Active Monitoring,
Given Varying Monitoring Durations and Risks for Symptomatic Infection After Exposure*
Monitoring
Duration
Mean Estimated Number of Undetected Symptomatic
Infections per 10 000 Monitored Persons (99th Percentile)
Low Risk







7 d 0.2 (0.4) 2.1 (3.6) 21.2 (36.5) 2120.6 (3648.5)
14 d 0.0 (0.0) 0.1 (0.5) 1.0 (4.8) 100.9 (481.7)
21 d 0.0 (0.0) 0.0 (0.1) 0.1 (0.8) 9.5 (82.5)
28 d 0.0 (0.0) 0.0 (0.0) 0.0 (0.2) 1.4 (17.8)
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
* Estimates were generated from a probabilistic model using the incubation period estimates from the log-normal model.
Figure 3. Proportion of known symptomatic SARS-CoV-2
infections that have yet to develop symptoms, by number
of days since infection, using bootstrapped estimates from














































The solid line represents the mean estimate, the dashed line repre-
sents the 99th percentile estimate, and the dotted line represents
the first percentile estimate. See Table 2 for exact estimates at
various time points and at different levels of population risk for
symptomatic infection. SARS-CoV-2 = severe acute respiratory syn-
drome coronavirus 2.
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rately accounts for the full distribution of possible incu-
bation periods.
Although our results support current proposals for
the length of quarantine or active monitoring of per-
sons potentially exposed to SARS-CoV-2, longer moni-
toring periods might be justified in extreme cases.
Among those who are infected and will develop symp-
toms, we expect 101 in 10 000 (99th percentile, 482)
will do so after the end of a 14-day monitoring period
(Table 2 and Figure 3), and our analyses do not pre-
clude this estimate from being higher. Although it is
essential to weigh the costs of extending active moni-
toring or quarantine against the potential or perceived
costs of failing to identify a symptomatic case, there
may be high-risk scenarios (for example, a health care
worker who cared for a COVID-19 patient while not
wearing personal protective equipment) where it could
be prudent to extend the period of active monitoring.
This analysis has several important limitations. Our
data include early case reports, with associated uncer-
tainty in the intervals of exposure and symptom onset.
We have used conservative bounds of possible expo-
sure and symptom onset where exact times were not
known, but there may be further inaccuracy in these
data that we have not considered. We have exclusively
considered reported, confirmed cases of COVID-19,
which may overrepresent hospitalized persons and oth-
ers with severe symptoms, although we note that the
proportion of mild cases detected has increased as sur-
veillance and monitoring systems have been strength-
ened. The incubation period for these severe cases
may differ from that of less severe or subclinical infec-
tions and is not typically an applicable measure for
those with asymptomatic infections.
Our model assumes a constant risk for SARS-CoV-2
infection in Wuhan from 1 December 2019 to 30 Janu-
ary 2020, based on the date of symptom onset of the
first known case and the last known possible exposure
within Wuhan in our data set. This is a simplification of
infection risk, given that the outbreak has shifted from a
likely common-source outbreak associated with a sea-
food market to human-to-human transmission. More-
over, phylogenetic analysis of 38 SARS-CoV-2 genomes
suggests that the virus may have been circulating be-
fore December 2019 (19). To test the sensitivity of our
estimates to that assumption, we performed an analysis
where cases with unknown lower bounds on exposure
were set to 1 December 2018, a full year earlier than in
our primary analysis. Changing this assumption had lit-
tle effect on the estimates of the median (0.2 day lon-
ger than for the overall estimate) and the 97.5th quan-
tile (0.1 day longer) of the incubation period. In data
sets such as ours, where we have adequate observa-
tions with well-defined minimum and maximum possi-
ble incubation periods for many cases, extending the
universal lower bound has little bearing on the overall
estimates.
This work provides additional evidence for a me-
dian incubation period for COVID-19 of approximately
5 days, similar to SARS. Assuming infection occurs at
the initiation of monitoring, our estimates suggest that
101 out of every 10 000 cases will develop symptoms
after 14 days of active monitoring or quarantine.
Whether this rate is acceptable depends on the ex-
pected risk for infection in the population being moni-
tored and considered judgment about the cost of miss-
ing cases (14). Combining these judgments with the
estimates presented here can help public health offi-
cials to set rational and evidence-based COVID-19 con-
trol policies.
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Appendix Table 1. Percentiles of SARS-CoV-2 Incubation Period From Selected Sensitivity Analyses*
Analysis Incubation Period (95% CI), d
2.5th Percentile 25th Percentile 50th Percentile 75th Percentile 97.5th Percentile
Main (n = 181) 2.2 (1.8–2.9) 3.8 (3.3–4.4) 5.1 (4.5–5.8) 6.7 (5.7–7.9) 11.5 (8.2–15.6)
Fever (n = 99) 2.6 (2.1–3.7) 4.4 (3.8–5.2) 5.7 (4.9–6.8) 7.5 (6.0–9.2) 12.5 (8.2–17.7)
Non-mainland (n = 108) 2.1 (1.5–3.2) 3.9 (3.2–5.1) 5.5 (4.4–7.0) 7.7 (5.4–10.3) 14.7 (7.4–22.6)
Mainland (n = 73) 2.5 (1.9–3.5) 3.8 (3.3–4.6) 4.8 (4.2–5.6) 6.0 (4.9–7.1) 9.2 (6.4–12.5)
EL-2018 (n = 181) 2.4 (1.8–3.1) 4.0 (3.5–4.6) 5.3 (4.7–6.0) 6.9 (5.8–8.4) 11.6 (8.1–16.4)
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
* Using the log-normal model, we estimated the incubation period for several subsets. The first analysis looked at time to fever onset, as opposed
to time to first symptom onset as used in the main analysis. The second and third analyses estimated the incubation period for cases outside and
within mainland China, respectively. To test the effect of our assumption that the exposure window for Wuhan residents started on 1 December
2019, we used an extreme assumption that the exposure window instead started on 1 December 2018 (EL-2018) and found little change in our
estimates.
Appendix Table 2. Parameter Estimates for Various
Parametric Distributions of the Incubation Period of
SARS-CoV-2 Using 181 Confirmed Cases*
Distribution Estimate (95% CI)
Parameter 1 Parameter 2
Log-normal 1.621 (1.504–1.755) 0.418 (0.271–0.542)
Gamma 5.807 (3.585–13.865) 0.948 (0.368–1.696)
Weibull 2.453 (1.917–4.171) 6.258 (5.355–7.260)
Erlang 6 (3–11) 0.880 (0.484–1.895)
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
* For the log-normal distribution, parameter 1 and parameter 2 are the
mean and SD of the natural logarithm of the distribution, respectively.
For all other distributions, parameter 1 and parameter 2 are the shape
and scale parameters, respectively.
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